RPS6KA3 and melanoma: Furthermore, there is more expression of RSK2 in vemurafenib-resistant melanoma cells compare with vemurafenib-sensitive cells, and silencing the expression of RSK2 could increase the sensitivity of A375-VR cells to vemurafenib.